BBraingaze
Braingaze is a digital cognitive health company that uses a patented eye-movement biomarker (small involuntary eye movements captured during short gaze-controlled tasks) plus AI to support objective diagnosis and therapy for ADHD, autism and other neurodevelopmental/neurocognitive conditions. Its products are BGaze Clinic, a ~12-minute CE-marked clinician assessment claiming up to 92% accuracy, and BGaze Focus, gaze-controlled therapeutic games; it cites 6,000+ diagnoses supported and 20+ peer-reviewed studies with partners including King's College London and NHS trusts. Founded in 2013 as a University of Barcelona / ICREA spin-off based in Mataró (Barcelona), it raised a €1.5M round in March 2024 and moved its headquarters to the London area while keeping its Spanish operations; it is a small team (2-10 employees).
Profile updated 5 Sep 2026
Founders
Global models
Investors 3
A
O
RFunding rounds 1
News & media 6
| Published | Article |
|---|---|
| 2026-05-27 |
Mindset-XR Innovation Support Programme company spotlight: Braingaze ↗
Health Innovation Network
|
| 2025-09-26 |
£3.6 million Innovate UK funding granted to 17 digital mental health tools ↗
HTN Health Tech News
|
| 2025-01-30 |
Braingaze Launches BGaze Focus: sign up as an exclusive beta tester to gain early access ↗
DigitalHealth.London
|
| 2024-10-07 |
Cohort Seven of the DigitalHealth.London Launchpad Announced ↗
DigitalHealth.London
|
| 2024-04-16 |
Tris Pharma Launches Digital Health Business to Develop and Commercialize Digital Products for ADHD ↗
Business Wire
|
| 2024-03-07 |
Braingaze Raises 1.5 Million to Develop Cognitive Health Solutions ↗
Born2Invest
|